Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
Anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia requires the use of other anticoagulants. We report a case in whom this was achieved using the heparinoid danaparoid (Orgaran). Based on our experience and a review of the literature, we provide guidelines for managing these rare patients. A danaparoid dose substantially lower than that recommended by the manufacturer may minimize bleeding complications.
Gillis
S
S
Department of Haematology, Hadassah University Medical Centre, Ein Karem, Jerusalem, Israel.
Merin
G
G
Zahger
D
D
Deeb
M
M
Drenger
B
B
Hyam
E
E
Eldor
A
A
D000925:Anticoagulants / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; C035838:danaparoid